| Literature DB >> 31127908 |
Mahnaz Ramezani1, Mahin Ramezani2,3, Ali Darekordi3, Gholamhossein Hassanshahi4, Mohammad Reza Mirzaei4,5.
Abstract
Objectives: Hepatocellular carcinoma is one of the most frequent cancers worldwide, for the treatment of which various therapy protocols and drugs have been introduced; however, none of them has suppressed cancer tissues completely. New research programs have been developed on cancer and the accompanied effects of novel synthesized compounds on cancer cell lines. Our latest reports on the molecular basis of cancer revealed a pattern of changes in gene expression triggered in the cancer pathway.Entities:
Keywords: Pyrrolidine-2-carboxamide compound; HepG2 cells; Apoptosis pathway
Mesh:
Substances:
Year: 2019 PMID: 31127908 PMCID: PMC6857876 DOI: 10.31557/APJCP.2019.20.5.1457
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Figure 1The Chemical Composition Image of (2R, 4S)-N-(2, 5-difluorophenyl)-4-Hydroxy-1-(2, 2, 2-Trifluoroacetyl) Pyrrolidine-2-Carboxamide (C13H11F5N2O3) (Darehkordi and Ramezani, 2017).
Gene’s up/down-Regulated after Pyrrolidine-2-Carboxamide Treatment
| Gene symbol | Protein/gene name | Activity | Fold changes |
|---|---|---|---|
| V-at murine thymoma viral oncogene homolog 1 | Anti-apoptosis | 42.5 | |
| BCL2-associated athanogene 3 | Anti-apoptosis | 6.15 | |
| BCL2-associated X protein | Pro-apoptosis | -7.07 | |
| B-cell CLL/lymphoma 2 | Pro-apoptosis | -9.19 | |
| BCL2-related protein A1 | Pro-apoptosis | 23.21 | |
| BCL2-like 11 (apoptosis facilitator) | Pro-apoptosis | -17.94 | |
| BCL2-associated transcription factor 1 | Pro-apoptosis | 5.15 | |
| Bifunctional apoptosis regulator | Anti-apoptosis | 5.56 | |
| BH3 interacting domain death agonist | Pro-apoptosis | -4.21 | |
| BCL2-interacting killer (apoptosis-inducing) | Pro-apoptosis | -36.51 | |
| Baculoviral IAP repeat containing 2 | Anti-apoptosis | 30 | |
| Baculoviral IAP repeat containing 3 | Anti-apoptosis | 7.585 | |
| Baculoviral IAP repeat containing 6 | Anti-apoptosis | -25.17 | |
| BCL2/adenovirus E1B 19kDa interacting protein 1 | Anti-apoptosis | -8.95 | |
| BCL2/adenovirus E1B 19kDa interacting protein 3 | Anti-apoptosis | -70.13 | |
| V-RAF murine sarcoma viral oncogene homolog B1 | Anti-apoptosis | -18.48 | |
| Caspase 10, apoptosis-related cysteine peptidase | Pro-apoptosis | -11.81 | |
| Protein/gene name | Activity | Fold changes | |
| Caspase 14, apoptosis-related cysteine peptidase | Pro-apoptosis | -26.86 | |
| Caspase 3, apoptosis-related cysteine peptidase | Pro-apoptosis | 9.57 | |
| Caspase 5, apoptosis-related cysteine peptidase | Pro-apoptosis | 34.33 | |
| Caspase 8, apoptosis-related cysteine peptidase | Pro-apoptosis | -18.82 | |
| CD40 ligand | Anti-apoptosis | -47.94 | |
| Cell death-inducing DFFA-like effector b | Pro-apoptosis | -12.94 | |
| Fas ligand (TNF superfamily, member 6) | Pro-apoptosis | 17.42 | |
| Insulin-like growth factor 1 receptor | Anti-apoptosis | -9.75 | |
| Receptor-interacting serine-threonine kinase 2 | Anti-apoptosis | -4.53 | |
| Tumor necrosis factor | Pro-apoptosis | 25.99 | |
| Tumor necrosis factor receptor superfamily, member 10a | Death domain proteins | -85.66 | |
| Tumor necrosis factor receptor superfamily, member 10b | Death domain proteins | -74.28 | |
| Tumor necrosis factor receptor superfamily, member 1A | Death domain proteins | -5.2 | |
| Tumor necrosis factor (ligand) superfamily, member 10 | Pro-apoptosis | -23.63 | |
| Tumor protein p53 | Pro-apoptosis | 36.38 | |
| Tumor protein p73 | Pro-apoptosis | -4.19 |
Figure 2The Scatter Plot Created in the PCR Array Data Analysis Web Portal Compares the Normalized Expression of Each Gene on PCR Array between 2 Groups. The upper left section (red dots) indicates upregulated genes, while the lower right section (green dots) indicates downregulated genes and the black dots indicates unchanged expressions of the genes.
A Complete List of Apoptotic Genes’ Expression Alteration in HepG2 Cell Line
| No | Regulation intensity | Position in PCR panel | Gene symbol | fold regulation |
|---|---|---|---|---|
| 1 | ↑↑↑↑↑ | A02 | 42.5 | |
| 2 | ↑↑ | A06 | 6.157 | |
| 3 | ↑↑↑↑↑ | A12 | 23.21 | |
| 4 | ↑↑ | B02 | 2.9737 | |
| 5 | ↑↑ | B04 | 2.5396 | |
| 6 | ↑↑ | B05 | 5.5132 | |
| 7 | ↑↑↑↑↑ | B10 | 30.0046 | |
| 8 | ↑↑ | B11 | 7.585 | |
| 9 | ↑↑ | C08 | 2.399 | |
| 10 | ↑↑ | D03 | 9.577 | |
| 11 | ↑↑↑↑↑ | D05 | 34.33 | |
| 12 | ↑↑ | D07 | 3.6785 | |
| 13 | ↑↑ | D10 | 3.9391 | |
| 14 | ↑↑↑↑ | E08 | 17.423 | |
| 15 | ↑↑↑↑↑ | F06 | 25.9996 | |
| 16 | ↑↑↑↑↑ | G06 | 36.3841 | |
| 17 | ↑↑↑↑ | E08 | 17.423 | |
| 18 | ↔ | A01 | -1.3157 | |
| 19 | ↔ | A03 | -1.1866 | |
| 20 | ↔ | A05 | 1.0105 | |
| 21 | ↔ | A08 | 1.4554 | |
| 22 | ↔ | A10 | -1.1522 | |
| 23 | ↔ | B09 | 1.4413 | |
| 24 | ↔ | B12 | -1.1584 | |
| 25 | ↔ | C04 | -1.4684 | |
| 26 | ↔ | C06 | 1.0441 | |
| 27 | ↔ | D04 | -1.0249 | |
| 28 | ↔ | D06 | -1.9333 | |
| 29 | ↔ | D09 | 1.6979 | |
| 30 | ↔ | E03 | 1.6262 | |
| 31 | ↔ | E04 | 1.436 | |
| 32 | ↔ | E07 | -1.083 | |
| 33 | ↔ | E07 | -1.083 | |
| 34 | ↔ | E10 | -1.5854 | |
| 40 | ↓↓ | A09 | -7.0745 | |
| 41 | ↓↓ | A11 | -9.1946 | |
| 42 | ↓↓↓↓ | B03 | -17.9496 | |
| 43 | ↓ | B07 | -4.2116 | |
| 44 | ↓↓↓↓↓ | B08 | -36.5133 | |
| 45 | ↓↓↓↓↓ | C01 | -25.1791 | |
| 46 | ↓ | C02 | -2.1114 | |
| 47 | ↓↓ | C03 | -8.9569 | |
| 49 | ↓↓↓↓ | C07 | -18.4811 | |
| 50 | ↓ | C09 | -2.7074 | |
| 51 | ↓ | C10 | -3.6587 | |
| 52 | ↓ | C11 | -2.1089 | |
| 53 | ↓↓↓ | C12 | -11.881 | |
| 54 | ↓↓↓↓ | D08 | -18.8262 | |
| 55 | ↓↓↓↓↓ | D11 | -47.9471 | |
| 56 | ↓ | D12 | -3.6587 | |
| 57 | ↓↓↓ | E02 | -12.9436 | |
| 58 | ↓ | E05 | -3.6587 | |
| 59 | ↓ | E09 | -3.6587 | |
| 60 | ↓↓ | E11 | -9.7576 | |
| 61 | ↓ | F02 | -3.6587 | |
| 62 | ↓ | F03 | -3.6587 | |
| 63 | ↓ | F05 | -4.5391 | |
| 64 | ↓ | F09 | -3.6587 | |
| 65 | ↓↓ | F10 | -5.2093 | |
| 66 | ↓ | F11 | -3.6587 | |
| 67 | ↓ | F12 | -3.6587 | |
| 68 | ↓ | G02 | -3.6587 | |
| 69 | ↓↓↓↓↓ | G03 | -23.6357 | |
| 70 | ↓ | G04 | -3.6587 | |
| 71 | ↓ | G05 | -3.6587 | |
| 72 | ↓ | G07 | -3.6587 | |
| 73 | ↓ | G08 | -4.1904 | |
| 74 | ↓ | G09 | -3.6587 |
*↑, Up-regulation (↑: 2–5, ↑↑: 5–10, ↑↑↑: 10–15, ↑↑↑↑: 15–20, and ↑↑↑↑↑: more than 20-folds); ** ↓, Down-regulation (↓: 2–5, ↓↓: 5–10, ↓↓↓: 10–15, ↓↓↓↓: 15–20, and ↓↓↓↓↓ more than 20-folds); ***↔, No regulation changed